Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex®

  • 19 Accesses

  • 12 Citations

Summary

Eleven patients with hyperlipoproteinaemia type II A, who were relatively resistant to hypolipidaemic drugs, were treated for four to six months with an anion exchange resin, Secholex® (PDX chloride), 15 g per day. The mean monthly plasma cholesterol level decreased by 10–18% (p<0.01 andp<0.001 respectively) from its pre-treatment value of 431±50 mg/100 ml (mean ±95% confidence limits). The reduction of plasma cholesterol was due mainly to a decrease in low density lipoproteins (LDL) of 50 mg/100 ml (p<0.01). Very low density lipoproteins (VLDL) were moderately (p<0.05) reduced and high density lipoproteins (HDL) remained unchanged. The mean pretreatment plasma triglyceride level (110±30 mg/100 ml) did not alter significantly. Nine of the patients had previously received clofibrate and in them Secholex reduced plasma cholesterol by 17% and clofibrate by 6%. Excluding one patient on clofibrate who had an unexpected increase in plasma cholesterol, there was little difference between the efficacy of clofibrate and Secholex. After four months two patients withdrew from the trial because of constipation. There was slight transient increase in mean serum alkaline phosphatase and a decrease in serum uric acid during treatment with Secholex.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bergen, S.S., Jr., van Itallie, T.B., Tennent, D.M., Sebrell, W.H.: Effect of anion exchange resin on serum cholesterol in man. Proc. Soc. exp. Biol. (N.Y.)102, 676–679 (1959)

  2. 2.

    Bressler, R., Nowlin, J., Bogdonoff, M.D.: Treatment of hypercholesterolemia and hypertriglyceridemia by anion exchange resin. South. med. J. (Bgham, Ala.)59, 1097–1103 (1966)

  3. 3.

    Burstein, M., Samaille, J.: Sur un dosage rapide du cholesterol lié aux α- et aux β-lipoprotéines du sérum. Clin. chim. Acta19, 493–498 (1959)

  4. 4.

    Carlson, L.A.: Determination of serum glycerides. Acta Soc. Med. upsalien.64, 208–213 (1959)

  5. 5.

    Cramér, K., Isaksson, B.: An evaluation of the Theorell method for the determination of total serum cholesterol. Scand. J. clin. Lab. Invest.11, 213–216 (1959)

  6. 6.

    Fallon, H.J., Woods, J.W.: Response of hyperlipoproteinemia to cholestyramine resin. J. Amer. med. Ass.204, 1161–1164 (1968)

  7. 7.

    Frederickson, D.S., Levy, R.I.: Treatment of essential hyperlipidaemia. Lancet1970 I, 191–192

  8. 8.

    Glueck, C.J., Ford, S., Scheel, D., Steiner, P.: Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia. J. Amer. med. Ass.222, 676–681 (1972)

  9. 9.

    Gustafson, A., Alaupovic, P., Furman, R.H.: Studies of the composition and structure of serum lipoproteins: Isolation, purification, and characterization of very low density lipoproteins of human serum. Biochemistry4, 596–605 (1965)

  10. 10.

    Gustafson, A., Sannerstedt, R.: Drug treatment of lipoproteinemia type II b. Effect on plasma lipids of a new phenoxyacetic acid derivative, clofibrate and nicotinic acid. Europ. J. clin. Pharmacol.5, 259–264 (1973)

  11. 11.

    Hashim, S.A., van Itallie, T.B.: Cholestyramine resin therapy for hypercholesterolemia. J. Amer. med. Ass.192, 289–293 (1965)

  12. 12.

    Howard, A.N., Hyams, D.E.: Combined use of clofibrate and cholestyramine or DEAE-Sephadex in hypercholesterolaemia. Brit. med. J.1971 III, 25–27

  13. 13.

    Jones, R.J., Dobrilovic, L.: Lipoprotein lipid alterations with cholestyramine administration. J. Lab. clin. Med.75, 953–966 (1970)

  14. 14.

    Langer, T., Levy, R.I.: Acute muscular syndrome associated with administration of clofibrate. New Engl. J. Med.279, 856–858 (1968)

  15. 15.

    Leppänen, V.: Evaluation of the p-toluene-sulfonic acid method for quantitative determination of total cholesterol in serum. Scand. J. clin. Lab. Invest.8, 201–206 (1956)

  16. 16.

    Nye, E.R., Jackson, D., Hunter, J.D.: Treatment of hypercholesterolaemia with colestipol: A bile sequestrating agent. N. Z. med. J.76, 12–16 (1972)

  17. 17.

    Parkinson, T.M.: Hypolipidemic effects of orally administered dextran and cellulose anion exchangers in cockerels and dogs. J. Lipid Res.8, 24–29 (1967a)

  18. 18.

    Parkinson, T.M.: Metabolism of orally administered dextran and “Sephadex“ derivatives in the rat. Nature215, 415–416 (1967b)

  19. 19.

    Rapp, W., Kahlke, W.: Lipoprotein-electrophoresis in agarosegel. Clin. chim. Acta19, 493–498 (1959)

  20. 20.

    Ryan, J.R., Jain, A.: The effect of colestipol or cholestyramine on serum cholesterol and triglycerides in a longterm controlled study. J. clin. Pharmacol.12, 268–273 (1972)

  21. 21.

    Strisower, E.H., Adamson, G., Strisower, B.: Treatment of hyperlipidemias. Amer. J. Med.45, 488–501 (1968)

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gustafson, A., Lanner, Å. Treatment of hyperlipoproteinaemia type II a with a new anion exchange resin Secholex® . Eur J Clin Pharmacol 7, 65–69 (1974). https://doi.org/10.1007/BF00614393

Download citation

Key words

  • PDX chloride
  • cholesterol
  • clofibrate
  • hyperlipoproteinaemia type II
  • bile acid sequestrant